Research Briefs: CardioFocus Trial Enrollment; Nerve Stim For Headaches; Cataract Removal
This article was originally published in The Gray Sheet
Executive Summary
Enrollment in CardioFocus’ U.S. pivotal trial of the HeartLight endoscopic atrial fibrillation ablation system is complete. A small study shows that small wires implanted in the head may cure chronic headaches. Biolase and Auris announce plans to build a cataract removal robot.
You may also be interested in...
HRS In Brief
Data highlighted earlier this month at the Heart Rhythm Society annual conference in Boston include results for new ablation systems, quadripolar leads and antibacterial cardiac implant wraps.
CardioFocus Piles Up Data On HeartLight Laser AF Ablation Catheter
In addition to the more than 1,300 ablation procedures completed outside the U.S. with the unique visually guided ablation catheter, the venture-backed company is conducting an IDE trial in 21 U.S. centers, which it expects to complete in 2014.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.